Document:

Form of Agreement

 Exhibit 10.1 
 AGREEMENT 
 This Agreement (this “Agreement”) is dated as of October 16, 2006,
among Cell Therapeutics, Inc., a Washington corporation (the “Company”), and the investor identified on the signature page hereto (the “Investor”). 
 WHEREAS, the Company and the Investor are party to a Securities Purchase Agreement, dated as of September 18, 2006 (the “Purchase
Agreement”), pursuant to which the Investor purchased shares of the Company’s common stock, no par value (the “Common Stock”); and 
 WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company and the Investor desire to void the sale of the above referenced transaction to the extent more fully described in this
Agreement. 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable
consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Investor agree as follows: 
 1.
Transaction. As soon as practicable following the date of this Agreement, the parties agree that (i) the Investor will instruct its broker to deliver to the Company
[            ] shares of Common Stock (the “Shares”) via the Depository Trust Company Deposit Withdrawal Agent Commission System and (ii) the Company will deliver to
the Investor $[            ] in immediately available funds via wire transfer to the account specified in writing by the Investor, which amount is equal to the number of Shares times
the Per Share Purchase Price as set forth in the Purchase Agreement. 
 2. Indemnification. The Company shall indemnify and
hold harmless Investor and its officers, directors, employees, stockholders, representatives, agents, successors and permitted assigns from and against the entirety of any and all actions, suits, proceedings, hearings, investigations, charges,
complaints, claims, demands, injunctions, judgments, orders, decrees, rulings, damages, losses, liabilities, dues, penalties, fines, costs, obligations, taxes, encumbrances, settlement costs and fees and expenses (including, without limitation,
court costs and reasonable attorneys’ fees and expenses) in connection with, resulting from, arising out of or relating to the transaction contemplated by this Agreement or a breach of this Agreement by the Company. 
 3. Entire Agreement. This Agreement and the Purchase Agreement contain the entire understanding of the parties with respect to the
subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 
 4. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. 
 5. Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized signatories as of the date first indicated above. 
  

													
	CELL THERAPEUTICS, INC.	 		 	[INVESTOR NAME]
					
	By:	 	/s/ James A. Bianco, M.D.	 		 	By:	 	[/s/ Investor Signatory]
		 	 Name:
	 	 James A. Bianco, M.D.
	 		 		 	 Name:
	 	
		 	 Title:
	 	 President and Chief Executive Officer
	 		 		 	 Title:Form of Warrant Repurchase Agreement

 Exhibit 10.2 
 WARRANT REPURCHASE AGREEMENT 
 This Warrant Repurchase Agreement (this “Agreement”)
is dated as of October 16, 2006, among Cell Therapeutics, Inc., a Washington corporation (the “Company”), and the warrant holder identified on the signature page hereto (the “Holder”). 
 WHEREAS, the Company and the Holder are party to a Securities Purchase Agreement, dated as of September 18, 2006 (the “Purchase
Agreement”), pursuant to which the Holder received that Greenshoe Common Stock Purchase Warrant to purchase the number of shares of Common Stock set forth on the signature page hereto (the “Warrant”); 
 WHEREAS, the Company wishes to repurchase the Warrant from the Holder at a price of $0.20 per share issuable upon exercise of the Warrant (the
“Repurchase Price”); and 
 WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company and
the Holder desire to void the sale of the above referenced transaction to the extent more fully described in this Agreement. 
 NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Holder agree as follows: 
 1. Repurchase. As soon as practicable following the date of this Agreement, the parties agree that (i) the Holder will deliver the
Warrant to the Company and (ii) within one business day following receipt of the Warrant, the Company will wire to the Holder an amount equal to the Repurchase Price in immediately available funds to the account specified in writing by the
Holder. 
 2. Indemnification. The Company shall indemnify and hold harmless Holder and its officers, directors, employees,
stockholders, representatives, agents, successors and permitted assigns from and against the entirety of any and all actions, suits, proceedings, hearings, investigations, charges, complaints, claims, demands, injunctions, judgments, orders,
decrees, rulings, damages, losses, liabilities, dues, penalties, fines, costs, obligations, taxes, encumbrances, settlement costs and fees and expenses (including, without limitation, court costs and reasonable attorneys’ fees and expenses) in
connection with, resulting from, arising out of or relating to the transaction contemplated by this Agreement or a breach of this Agreement by the Company. 
 3. Entire Agreement. This Agreement and the Purchase Agreement contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 
 4. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal
laws of the State of New York, without regard to the principles of conflicts of law thereof. 
 5. Counterparts. This Agreement
may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Repurchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

													
	CELL THERAPEUTICS, INC.	 		 	[HOLDER NAME]
					
	By:	 	/s/ James A. Bianco, M.D.	 		 	By:	 	[/s/ Holder Signatory]
		 	 Name:
	 	 James A. Bianco, M.D.
	 		 		 	 Name:
	 	
		 	 Title:
	 	 President and Chief Executive Officer
	 		 		 	 Title:
	 	
					
		 		 		 		 	 Shares issuable upon

		 		 		 		 	exercise of the Warrant: [                    ]Employment Offer Letter

 Exhibit 10.96 
 September 6, 2006 
 Gregory Wrenn 
 Re: Employment Offer 
 Dear Gregory, 
 On behalf of
Borland Software Corporation (“Borland”), I am pleased to extend an offer of employment to you for the position of Senior Vice President and General Counsel reporting to me. This letter sets out the terms of your employment with Borland
which will start on October 1, 2006. Please indicate start date below. This offer and your Start Date are contingent upon successful completion of references, employment verification and a background check. 
 In consideration for your service to Borland, you will be paid a base salary of $280,000.00 per year, less applicable taxes and other withholdings in
accordance with Borland’s standard payroll practices. Beginning January 1, 2007, you will be eligible for the Incentive Compensation Program (ICP) specific to the senior management team. Your annual target bonus will be equal to 50% of
your base pay. In addition, you will be eligible to participate in various Borland fringe benefit plans, including: Group Health Insurance, Flexible Spending Accounts, 401(k) Savings Plan, Employee Stock Purchase Plan, Tuition Reimbursement and the
vacation program. Borland reserves the right to modify employee benefit plans and policies, as it deems necessary. These benefits will be explained to you during your employee orientation. 
 Also, you will receive a signing bonus of $35,000.00, less required payroll deductions and withholdings (the “Advanced Bonus”) payable on the
last pay period in February, 2007. 
 Subject to the approval of the Compensation Committee of the Board of you will be granted an option to
purchase 125,000 shares of Borland common stock under Borland’s Stock Plans at an exercise price equal to the fair market value of that stock on your option grant date. This option will vest over a period of four years, with  1/4 of the number of shares vesting one year following your Start Date and 1/48 of the shares vesting monthly
thereafter, until all shares are vested; provided however all shares will be subject to acceleration in the event of a change of control of Borland and you are terminated without cause in connection therewith. 

 The option will be subject to the terms and conditions of the Borland Stock Option Plan and related
standard form of stock option agreement and stock acceleration addendum, which you will be required to sign as a condition of receiving the option. 
 In addition, subject to the approval of the Board of Directors of Borland, the Compensation Committee of the Board of Directors, or Executive Option Committee acting by delegation of authority from the Compensation Committee of the Board of
Directors, you will be issued 50,000 shares of restricted Borland common stock under Borland’s Stock Plans. The shares will vest over a period of two years, with  1/2 of the number of shares vesting one year following your Start Date and 1/8 of the shares vesting quarterly thereafter, until all shares are vested; provided however all shares
will be subject to acceleration in the event of a change of control of Borland and you are terminated without cause in connection therewith. The shares will be subject to the terms and conditions of the Borland Stock Plan and related standard form
of restricted stock issuance agreement and stock acceleration addendum, which you will be required to sign as a condition of receiving the shares. 
 You shall be eligible for severance benefits in accordance with the attached Addendum to Employment Offer Letter for Severance Benefits, which you will be required to sign as a condition of receiving the benefits.

 Your employment with Borland is “at will”; it is for no specified term, and may be terminated by you or Borland at any time,
with or without cause or advance notice. Any contrary representations that may have been made to you are superseded by this offer. This is the full and complete agreement between you and Borland on this term. Although your job duties, title,
compensation and benefits, as well as Borland’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and
Borland’s Chief Executive Officer. 
 By accepting employment with Borland, you represent that you will not be acting in breach of any
agreement with any of your previous employers. Borland is very impressed with the skills and experience that you will bring to us and we hope that you will consider this offer carefully. Should you accept this offer, I would like to remind you that
it is Borland’s policy to avoid situations where information or materials might come into our hands that are considered proprietary by individuals or companies other than Borland. We are interested in employing you because of your skills and
abilities, not because of any trade secrets you have learned elsewhere. It is important that you take care not to bring, even inadvertently, any books, drawings, notes, materials, etc., except your personal effects as you leave your current
employer. Thus, you represent and warrant that you are not acting in breach of any non-competition, employment or other agreements with your current employer or any of your previous employers. 
 You understand that Borland may provide you with one or more types of equipment to help you perform your duties for Borland, including, but not limited
to, computers, cellular telephones and wireless messaging devices. You further understand that it is your obligation to take proper care of all such equipment during your employment, and to return such equipment to Borland in good working order
immediately upon the termination of your employment with Borland for any reason. If you fail to return any such equipment to Borland upon the termination of your employment, you hereby authorize Borland to deduct the cost of any unreturned equipment
from your final paycheck. 

 Like all Borland employees, you will be required, as a condition to your employment with Borland, to sign
Borland’s standard Employee Confidentiality and Assignment of Inventions Agreement, a copy of which is included with this letter. 
 As
part of your duties for Borland, you may be assigned to work onsite with a Borland customer. Some of these customers have additional requirements that they impose upon individuals who work onsite at their business, including background checks, drug
testing, and other such requirements. If you are assigned to work with such a customer, you will be given notice of the customer’s additional requirements and will be asked to consent to these requirements. 
 As a condition of your employment, you will be required to provide Borland with documents establishing your identity and right to work in the United
States. Those documents must be provided to Borland within three (3) business days after your Start Date. 
 To ensure the timely and
economical resolution of disputes that arise in connection with your employment with Borland, you and Borland agree that any and all disputes, claims, or causes of action (collectively, “Claims”) arising from or relating to the
enforcement, breach, performance or interpretation of this Agreement, your employment, or the termination of your employment (including, but not limited to, any Claims for compensation, benefits, stock or stock options, fraud or age, sex, race,
disability or other discrimination or harassment), shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Santa Clara County, California, conducted by Judicial Arbitration
and Mediation Services, Inc. (“JAMS”) under the applicable JAMS employment rules, or other arbitrator or arbitration rules to which you and Borland mutually agree. By agreeing to this arbitration procedure, both you and Borland waive the
right to resolve any such dispute through a trial by jury or judge or administrative proceeding. 
 The arbitrator shall: (a) have the
authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision, to include the arbitrator’s essential findings and
conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that you or Borland would be entitled to seek in a court of law. Borland shall pay all arbitrator and arbitration administrative fees in excess
of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either you or Borland from obtaining injunctive relief in court to prevent irreparable harm pending
the conclusion of any such arbitration. 
 This agreement and the other agreements referred to above constitute the entire agreement between
you and Borland regarding the terms and conditions of your employment, and they supersede all prior negotiations, representations or agreements, whether oral or written, between you and Borland. This agreement may only be modified by a document
signed by you and the Senior Vice President of Human Resources of Borland. 

 We look forward to working with you at Borland. Please sign and date this letter on the spaces provided
below to acknowledge your acceptance of the terms of this offer. This offer, if not accepted, will expire at the close of business on September 8, 2006. If you have any questions, please do not hesitate to call me at any time. 
  

			
	Sincerely,
	Borland Software Corporation
		
	By:	 	 /s/ Tod Nielsen

		 	Tod Nielsen
		 	President and Chief Executive Officer

 I have read the above employment offer and accept employment with Borland on the terms and conditions set
forth in this agreement. 
  

					
	 Date: September 7, 2006
	 	 /s/ Gregory Wrenn

		 	Gregory Wrenn
	
	Start Date: October 16, 2006

 Please send the original signed offer letter and the new-hire paperwork to Borland’s Human Resources
Department using the envelope provided.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]